ATE355522T1 - METHOD FOR MEASURING THE ACTIVITY OF G(ALPHA)I- OR G(ALPHA)O-COUPLED RECEPTORS USING CA2+ INFLUX IN CELLS - Google Patents

METHOD FOR MEASURING THE ACTIVITY OF G(ALPHA)I- OR G(ALPHA)O-COUPLED RECEPTORS USING CA2+ INFLUX IN CELLS

Info

Publication number
ATE355522T1
ATE355522T1 AT03789105T AT03789105T ATE355522T1 AT E355522 T1 ATE355522 T1 AT E355522T1 AT 03789105 T AT03789105 T AT 03789105T AT 03789105 T AT03789105 T AT 03789105T AT E355522 T1 ATE355522 T1 AT E355522T1
Authority
AT
Austria
Prior art keywords
alpha
measuring
influx
cells
activity
Prior art date
Application number
AT03789105T
Other languages
German (de)
Inventor
Erik James Wade
Elke Janocha
Tieno Germann
Gregor Bahrenberg
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of ATE355522T1 publication Critical patent/ATE355522T1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method of measuring the activation or deactivation of G(alpha)i- or G(alpha)o-coupled receptors, and methods of identifying agonists or antagonists of such receptors.
AT03789105T 2002-12-05 2003-12-04 METHOD FOR MEASURING THE ACTIVITY OF G(ALPHA)I- OR G(ALPHA)O-COUPLED RECEPTORS USING CA2+ INFLUX IN CELLS ATE355522T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10256947A DE10256947A1 (en) 2002-12-05 2002-12-05 Method for measuring the activity of G (alpha) i- or G (alpha) o-coupled receptors using Ca2 + influx in cells

Publications (1)

Publication Number Publication Date
ATE355522T1 true ATE355522T1 (en) 2006-03-15

Family

ID=32336022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789105T ATE355522T1 (en) 2002-12-05 2003-12-04 METHOD FOR MEASURING THE ACTIVITY OF G(ALPHA)I- OR G(ALPHA)O-COUPLED RECEPTORS USING CA2+ INFLUX IN CELLS

Country Status (7)

Country Link
US (2) US20050277110A1 (en)
EP (1) EP1570266B1 (en)
AT (1) ATE355522T1 (en)
AU (1) AU2003293742A1 (en)
DE (2) DE10256947A1 (en)
ES (1) ES2282718T3 (en)
WO (1) WO2004051264A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2034977B1 (en) 2006-04-21 2011-07-13 DSM IP Assets B.V. Use of opioid receptor antagonists
CN109946451B (en) * 2019-04-16 2022-05-20 浙江诺迦生物科技有限公司 Detection method and detection kit for cannabinoids active substances based on concentration change effect of intracellular free calcium ions
CN109946450B (en) * 2019-04-16 2022-04-19 浙江诺迦生物科技有限公司 Detection method and detection kit for opioid active substances based on concentration change effect of intracellular free calcium ions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US6383761B2 (en) * 1997-07-28 2002-05-07 The Regents Of The University Of California Methods and compositions for identifying modulators of G-protein-coupled receptors
US6709830B2 (en) * 1997-11-13 2004-03-23 The Regents Of The University Of California Methods for modulating the activation of a lymphocyte expressed G protein coupled receptor involved in cell proliferation, autoimmunity and inflammation
GB9903767D0 (en) * 1999-02-18 1999-04-14 Univ Glasgow Receptor assay
AU2000273414A1 (en) * 2000-02-07 2001-08-20 Tropix, Inc. Enzyme-based gprotein-coupled receptor assay
ATE330027T1 (en) * 2000-03-13 2006-07-15 Merck & Co Inc HIGH THROUGHPUT SCREENING BY MEASURING INTRACELLULAR CALCIUM LEVELS
US6448377B1 (en) * 2000-09-27 2002-09-10 The Board Of Trustees Of The Leland Stanford Junior University Modified G protein sunbunits
DE10123958A1 (en) * 2001-05-17 2002-11-28 Aventis Pharma Gmbh Identifying ligands for G protein-coupled receptors, useful for treating cardiovascular disease, by using calcium-sensitive fluorophores in cells expressing G alpha proteins

Also Published As

Publication number Publication date
AU2003293742A1 (en) 2004-06-23
ES2282718T3 (en) 2007-10-16
EP1570266A1 (en) 2005-09-07
US20050277110A1 (en) 2005-12-15
EP1570266B1 (en) 2007-02-28
DE50306697D1 (en) 2007-04-12
US7829300B2 (en) 2010-11-09
US20090136989A1 (en) 2009-05-28
WO2004051264A1 (en) 2004-06-17
DE10256947A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
ATE278803T1 (en) METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG EFFECTS
DE60334599D1 (en) Method and device for dialog management between user and agent
DE60329377D1 (en) METHOD OF FORECASTING SEPSIS IN A PATIENT WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS)
ATE480674T1 (en) METHOD AND SYSTEM FOR PERFORMING DETERMINATION OF THE POSITION OF A DEVICE
ATE385562T1 (en) MONITORING SYSTEM AND METHOD OF USE THEREOF
DE60324539D1 (en) DEVICE FOR SUPPORTING THE MEMORY AREA NETWORK SYSTEM CONSTRUCTION, METHOD FOR SUPPORTING THE SYSTEM CONSTRUCTION, AND PROGRAM FOR SUPPORTING THE SYSTEM CONSTRUCTION
DE50308558D1 (en) DEVICE FOR MEASURING BENTIFICITY OF FLAT SUBMISSIONS
DE60309453D1 (en) DEVICE FOR MANAGING A PATIENT TREATMENT PROGRAM
ATE464056T1 (en) METHOD FOR ACTIVATION OF NKT CELLS
ATE456666T1 (en) METHOD FOR EVALUATION OF RIBONUCLEOTIDE SEQUENCES
AR029838A1 (en) SUBSTITUTED BENZONITROGEN HETEROCICLES
ATE403151T1 (en) SUPPORT PLATE FOR PERFORMING FUNCTIONAL TESTS ON BIOLOGICAL CELLS AND METHOD FOR COATING THE SUPPORT PLATE
DE60326973D1 (en) BIOACTIVE COATING FOR MEDICAL DEVICE WITH KERATIN
DE602007010246D1 (en) PROCESS FOR BLOOD DETERMINATION
DE602006013604D1 (en) METHOD FOR DETERMINING RESPONSIVENESS AGAINST CHK1 INHIBITORS
ATE355522T1 (en) METHOD FOR MEASURING THE ACTIVITY OF G(ALPHA)I- OR G(ALPHA)O-COUPLED RECEPTORS USING CA2+ INFLUX IN CELLS
NZ594843A (en) Method or system using biomarkers for the monitoring of a treatment
DE60315575D1 (en) Method and device for the examination of surfaces
DE60303757D1 (en) Method and system for measuring low impedances
ATE408211T1 (en) METHOD FOR FORECASTING A TRAFFIC CONDITION IN A ROAD NETWORK AND TRAFFIC MANAGEMENT CENTRE
DE60318900D1 (en) NUCLEIC ACIDS, POLYPEPTIDES AND METHOD FOR MODULATING APOPTOSIS
ATA11452002A (en) METHOD AND DEVICE FOR MEASURING THE MACROMOLECULAR PROTON DENSITY
ATE392619T1 (en) METHOD FOR DIAGNOSING SYNOVIAL OR OSTEOARTICULAR DISEASES
DE60323319D1 (en) Apparatus and method for voice activity detection
DE50303478D1 (en) TEST SYSTEM FOR EVALUATING THE COMPATIBILITY OF BIOLOGICALLY ACTIVE SUBSTANCES WITH COPOLYMERS